Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746924 · ClinicalTrials.gov registry record · Phase 3
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by BeiGene.
- Active
- Registry status
- Phase 3
- Development phase
- 662
- Enrollment target
- 20
- Study locations
NCT04746924 is a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 662 participants, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT04746924, a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 662 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG Tislelizumab
- DRUG Ociperlimab
Study Locations (20)
Queensland
- Pindara Private Hospital - Benowa
- The Prince Charles Hospital - Chermside
- Mater Cancer Care Centre - South Brisbane
- John Flynn Private Hospital - Tugun
New South Wales
- Concord Repatriation General Hospital - Concord
- Northern Cancer Institute - St Leonards
- Calvary Mater Newcastle - Waratah
California
- Providence Medical Foundation St Jude Heritage Healthcare - Fullerton
- Valkyrie Clinical Trials - Los Angeles
Florida
- Ocala Oncology Center Pl Dba Florida Cancer Affiliates Ocala - Ocala
- Advent Health Cancer Institute - Orlando
Other
- Centro Medical Austral - Buenos Aires
- Centro Para La Atencion Del Paciente Oncologico (Caipo) - San Miguel de Tucumán
Indiana
- Goshen Center For Cancer Care - Goshen
Kentucky
- Baptist Health Lexington - Lexington
Louisiana
- University Medical Center New Orleans West Jefferson Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 662 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04746924
The ClinicalTrials.gov registry entry for NCT04746924 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 662 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT04746924 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Queensland, New South Wales, California.
Frequently Asked Questions
What is clinical trial NCT04746924 about?
NCT04746924 is a clinical study titled "A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer". The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.
What is the current status of trial NCT04746924?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 662 participants. The study started on 2021-06-08. Estimated completion is 2026-03-31.
What conditions does trial NCT04746924 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC.
What interventions are being tested in trial NCT04746924?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Tislelizumab (DRUG), Ociperlimab (DRUG).
Who is sponsoring clinical trial NCT04746924?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04746924 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.